Ber-H2 (anti-CD30)-saporin immunotoxin: A new tool for the treatment of Hodgkin's disease and CD30+ lymphoma: In vitro evaluation

P. L. Tazzari, A. Bolognesi, D. De Totero, B. Falini, R. M. Lemoli, M. R. Soria, S. Pileri, M. Gobbi, H. Stein, L. Flenghi, M. F. Martelli, F. Stirpe

Research output: Contribution to journalArticle

Abstract

An immunotoxin containing an anti-CD30 monoclonal antibody (Ber-H2) and saporin, a ribosome-inactivating protein type 1, is described. It specifically inhibits protein synthesis by Hodgkin derived target cell lines with a very high efficiency (IC50 ranging from 5 x 10-12 M to 5 x 10-14 M, as saporin), while irrelevant immunotoxins do not. Present results suggest that this immunotoxin could be used for in vivo therapy as well as for ex vivo bone marrow purging in Hodgkin's disease and CD30+ lymphomas.

Original languageEnglish
Pages (from-to)203-211
Number of pages9
JournalBritish Journal of Haematology
Volume81
Issue number2
Publication statusPublished - 1992

ASJC Scopus subject areas

  • Hematology

Fingerprint Dive into the research topics of 'Ber-H2 (anti-CD30)-saporin immunotoxin: A new tool for the treatment of Hodgkin's disease and CD30+ lymphoma: In vitro evaluation'. Together they form a unique fingerprint.

  • Cite this

    Tazzari, P. L., Bolognesi, A., De Totero, D., Falini, B., Lemoli, R. M., Soria, M. R., Pileri, S., Gobbi, M., Stein, H., Flenghi, L., Martelli, M. F., & Stirpe, F. (1992). Ber-H2 (anti-CD30)-saporin immunotoxin: A new tool for the treatment of Hodgkin's disease and CD30+ lymphoma: In vitro evaluation. British Journal of Haematology, 81(2), 203-211.